Alex joined DAVA CRO in March 2017, where he initially served in a variety of data analysis roles before turning his focus to managing the patient enrollment and pharmacovigilance processes for Arog Pharmaceuticals’ ongoing Phase III AML trials. Prior to joining the CRO, he spent several years working in academic research, including time as a lab manager in the Molecular Biology department at UT Southwestern Medical Center.
Alex received his undergraduate degree in Biochemistry and Cell Biology and Ecology and Evolutionary Biology from Rice University in 2013, followed by a Master of Public Health in Healthcare Management from the University of Texas in 2016.